SI2364137T1 - Farmacevtska suspenzija - Google Patents

Farmacevtska suspenzija

Info

Publication number
SI2364137T1
SI2364137T1 SI200931678A SI200931678A SI2364137T1 SI 2364137 T1 SI2364137 T1 SI 2364137T1 SI 200931678 A SI200931678 A SI 200931678A SI 200931678 A SI200931678 A SI 200931678A SI 2364137 T1 SI2364137 T1 SI 2364137T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical suspension
pharmaceutical
suspension
Prior art date
Application number
SI200931678A
Other languages
English (en)
Slovenian (sl)
Inventor
Bhagwati P. Kabra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2364137T1 publication Critical patent/SI2364137T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931678A 2008-12-05 2009-12-03 Farmacevtska suspenzija SI2364137T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008108P 2008-12-05 2008-12-05
PCT/US2009/066570 WO2010065730A2 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension
EP09768284.3A EP2364137B1 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension

Publications (1)

Publication Number Publication Date
SI2364137T1 true SI2364137T1 (sl) 2017-07-31

Family

ID=41562672

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931678A SI2364137T1 (sl) 2008-12-05 2009-12-03 Farmacevtska suspenzija

Country Status (17)

Country Link
US (1) US9707173B2 (enExample)
EP (1) EP2364137B1 (enExample)
JP (1) JP5661640B2 (enExample)
AR (1) AR074423A1 (enExample)
AU (1) AU2009322355B2 (enExample)
CA (1) CA2745123C (enExample)
CY (1) CY1119038T1 (enExample)
DK (1) DK2364137T3 (enExample)
ES (1) ES2630037T3 (enExample)
HR (1) HRP20170959T1 (enExample)
HU (1) HUE034662T2 (enExample)
LT (1) LT2364137T (enExample)
PL (1) PL2364137T3 (enExample)
PT (1) PT2364137T (enExample)
SI (1) SI2364137T1 (enExample)
TW (1) TW201023912A (enExample)
WO (1) WO2010065730A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
MX2013000578A (es) * 2010-07-21 2013-02-21 Alcon Res Ltd Composicion farmaceutica con caracteristicas de solubilidad incrementadas.
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
RS65207B1 (sr) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv Formulacije bedakvilina sa dugim delovanjem
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
US20220105100A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content
CA3268120A1 (en) * 2023-05-11 2024-11-14 Akums Drugs & Pharmaceuticals Limited OPHTHALMIC FORMULATION FREE OF BENZALKONIUM CHLORIDE

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5206267A (en) 1991-05-09 1993-04-27 Morton Shulman Pain controlling composition and method of preparation
US5338732A (en) 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5932572A (en) 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
EP0782850A4 (en) 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
AU718199B2 (en) 1996-12-13 2000-04-06 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
JPH10287552A (ja) 1997-04-11 1998-10-27 Kobayashi Seiyaku Kogyo Kk 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法
ES2227331T3 (es) 1997-07-29 2005-04-01 Alcon Laboratories, Inc. Soluciones de acondicionamiento para el cuidado de las lentes de contacto duras.
EP1213018A4 (en) * 1999-09-06 2004-04-14 Ono Pharmaceutical Co AGENTS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
MXPA02003130A (es) 1999-09-24 2004-04-21 Alcon Inc Formulaciones topicas en suspension que contienen ciprofloxacino y dexametasona.
JP2003533464A (ja) 2000-05-15 2003-11-11 フアルマシア・イタリア・エツセ・ピー・アー 安定化ステロイド懸濁液
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
EP1429780B1 (en) 2001-09-21 2005-12-21 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
EP1638941B1 (en) 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050245497A1 (en) 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CA2607608A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
PL1906916T3 (pl) 2005-05-10 2009-02-27 Alcon Inc Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP1962803A1 (en) 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
WO2008076819A2 (en) 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
KR20100051811A (ko) 2007-07-20 2010-05-18 알콘, 인코퍼레이티드 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
EP2072564B1 (de) 2007-12-19 2013-07-03 Sika Technology AG Einkomponentiger, feuchtigkeitshärtender Polymerschaum
JP5155767B2 (ja) 2008-08-04 2013-03-06 国立大学法人大阪大学 ガス検知素子
WO2010101971A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Also Published As

Publication number Publication date
AR074423A1 (es) 2011-01-19
AU2009322355A1 (en) 2010-06-10
CY1119038T1 (el) 2018-01-10
PL2364137T3 (pl) 2017-09-29
TW201023912A (en) 2010-07-01
ES2630037T3 (es) 2017-08-17
US20100144719A1 (en) 2010-06-10
PT2364137T (pt) 2017-07-10
CA2745123C (en) 2018-11-13
EP2364137A2 (en) 2011-09-14
LT2364137T (lt) 2017-06-26
HRP20170959T1 (hr) 2017-09-22
WO2010065730A2 (en) 2010-06-10
EP2364137B1 (en) 2017-03-29
AU2009322355B2 (en) 2015-11-05
US9707173B2 (en) 2017-07-18
HUE034662T2 (en) 2018-02-28
JP2012511009A (ja) 2012-05-17
WO2010065730A3 (en) 2011-04-14
JP5661640B2 (ja) 2015-01-28
CA2745123A1 (en) 2010-06-10
DK2364137T3 (en) 2017-07-10

Similar Documents

Publication Publication Date Title
SI2364137T1 (sl) Farmacevtska suspenzija
IL237392B (en) Pharmaceutical combination
GB0801876D0 (en) Suspension formulations
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
IL207378A0 (en) Pharmaceutical solid state forms
GB0810615D0 (en) Novel pharmaceutical
GB0816371D0 (en) Pharmaceutical compounds
EP2263891A4 (en) SUSPENSION SYSTEM
GB0812969D0 (en) Pharmaceutical compounds
PT2271618E (pt) Compostos farmacêuticos
GB0816370D0 (en) Pharmaceutical compounds
GB0913082D0 (en) Suspension device
HU0800591D0 (en) Stable pharmaceutical combination
IL208953A0 (en) Pharmaceutical combination
PL2309983T3 (pl) Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę
GB0810857D0 (en) Pharmaceutical compounds
GB0810617D0 (en) Novel pharmaceutical
HU0800414D0 (en) Pharmaceutical combination
GB0804486D0 (en) Novel pharmaceutical composituons
GB0702639D0 (en) Suspension means
GB0807502D0 (en) Pharmaceutical compounds
GB0820825D0 (en) Pharmaceutical compounds